Presidio Medical⢠Receives IDE Approval for Ultra Low Frequency (ULFâ˘) Neuromodulation Clinical Study and Appoints Dimas JimĂŠnez as Chief Financial Officer
SAN MATEO, Calif.--(BUSINESS WIRE)--Presidio Medical, Inc., a global clinical-stage medical device company developing a transformational Ultra Low Frequency (ULFâ˘) neuromodulation platform, receive...
3 months ago